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Objectives This study sought to investigate the effects of interventional renal sympathetic denervation (RD) on cardiorespi-
ratory response to exercise.
Background RD reduces blood pressure at rest in patients with resistant hypertension.
Methods We enrolled 46 patients with therapy-resistant hypertension as extended investigation of the Symplicity HTN-2
(Renal Denervation With Uncontrolled Hypertension) trial. Thirty-seven patients underwent bilateral RD and 9
patients were assigned to the control group. Cardiopulmonary exercise tests were performed at baseline and
3-month follow-up.
Results In the RD group, compared with baseline examination, blood pressure at rest and at maximum exercise after
3 months was significantly reduced by 31  13/9  13 mm Hg (p  0.0001) and by 21  20/5  14 mm Hg
(p  0.0001), respectively. Achieved work rate increased by 5  13 W (p  0.029) whereas peak oxygen up-
take remained unchanged. Blood pressure 2 min after exercise was significantly reduced by 29  17/8  15
mm Hg (p  0.001 for systolic blood pressure; p  0.002 for diastolic blood pressure). Heart rate at rest de-
creased after RD (4  11 beats/min; p  0.028), whereas maximum heart rate and heart rate increase during
exercise were not different. Heart rate recovery improved significantly by 4  7 beats/min after renal denerva-
tion (p  0.009). In the control group, there were no significant changes in blood pressure, heart rate, maximum
work rate, or ventilatory parameters after 3 months.
Conclusions RD reduces blood pressure during exercise without compromising chronotropic competence in patients with re-
sistant hypertension. Heart rate at rest decreased and heart rate recovery improved after the procedure. (Renal
Denervation With Uncontrolled Hypertension; [Symplicity HTN-2]; NCT00888433) (J Am Coll Cardiol 2011;58:
1176–82) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.05.036Renal sympathetic nerves are crucial for the development
and maintenance of arterial hypertension by regulating renin
release, tubular sodium reabsorption, and renal blood flow
(1). Afferent sympathetic nerves from the kidney contribute
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September 6, 2011:1176–82 Exercise Parameters After Renal Denervationenergy (3). A recently published multicenter, randomized
trial proved the efficacy of catheter-based renal sympathetic
denervation (RD) in patients with resistant hypertension
(4). The procedure was also shown to reduce renal and
central sympathetic activity and thereby to improve blood
pressure and glucose metabolism (5,6). However, sympa-
thetic nerve activity physiologically regulates the response to
physical stress, leading to increased heart rate, cardiac
output, blood pressure, and ventilation. The effects of RD
on these functions have not been investigated so far. In
particular, it is not known whether this new therapeutic
approach has a negative impact on chronotropic competence
and may therefore impair physical exercise capacity. Our
study investigated the effects of RD on the cardiopulmonary
response during cardiopulmonary exercise testing in patients
with resistant hypertension.
Methods
Study subjects. Twenty-eight patients were included in the
Symplicity HTN-2 (Renal Denervation With Uncontrolled
Hypertension) trial in Homburg/Saar and Cologne (4). The
current study was extended by including 18 patients with
the same inclusion and exclusion criteria. Eligible patients
were age 18 years and had an office blood pressure of
160 mm Hg (150 mm Hg for type 2 diabetic patients),
despite being treated with 3 antihypertensive drugs (in-
cluding a diuretic), with no changes in medication for a
minimum of 2 weeks prior to enrolment. Complete inclu-
sion and exclusion criteria of the Symplicity HTN-2 trial
were described elsewhere (4). The study was approved by
the local ethics committees in accordance with the Decla-
ration of Helsinki. Patients were treated between March
2009 and October 2010 with subsequent follow-up to 3
months. All patients gave written informed consent. Nine
patients were randomly assigned to a control group and 37
to an RD group in a 1:3 ratio. The RD procedure was
performed as described previously (4).
Cardiopulmonary exercise testing. Cardiopulmonary ex-
ercise testing (CPET) was performed in all patients after
randomization (baseline) and after 3 months. Patients
underwent symptom-limited CPET with breath-by-breath
gas exchange analyses using an Innocor spiroergometry
system (Innovision, Odense, Denmark) or a Masterscreen
CPX (Viasys, Berlin, Germany). Patients performed bicycle
exercise in a 45° semi-supine position lying on an ergomet-
rics 99EL reclining ergometer (Ergoline Cardio-Systems,
Bitz, Germany). The physician supervising the exercise
testing was blinded to the randomization. Resting blood
pressure was taken after the subject was sitting for at least 10
min. After adaptation to the mouthpiece at resting condi-
tions, exercise work rate was increased continuously by 15
W/min (ramp protocol) followed by a recovery phase for 4
min. Heart rate and cardiac rhythm was continuously
recorded with 12-lead electrocardiography throughout the
procedure. Blood pressure was measured in 2-min intervalsduring CPET and the recovery
period by an experienced physi-
cian using a manual sphygmo-
manometer. In each patient,
maximum achieved work rate,
peak oxygen consumption, oxy-
gen uptake at the anaerobic
threshold (AT), minute ventila-
tion, VE/VCO2 slope ( minute
entilation – carbon dioxide out-
ut relationship), and the respi-
atory exchange ratio ( carbon
ioxide output – oxygen uptake
elationship) were measured.
he V-slope, ventilatory equiva-
ents, and end-tidal pressure
ethods were used for determi-
ation of the AT (7). Both sys-
olic blood pressure (SBP) and
iastolic blood pressure (DBP) at
ecovery were defined as blood
ressure 2 min after termination
f exercise. Heart rate recovery (HRR) was defined as the
eduction in heart rate from peak exercise to the heart rate
min after the cessation of exercise.
tatistical analysis. Data are presented as mean  SD
nless otherwise specified. Comparisons within groups were
erformed using the Pearson chi-square test for categorical
ariables and the Wilcoxon rank sum test or an unpaired t
est for continuous variables where appropriate. For
etween-group changes, the repeated measures analysis of
ariance model was used, unless otherwise specified. All
tatistical analyses were performed with SPSS statistical
oftware (version 12.0, SPSS Inc., Chicago, Illinois).
esults
atients in the treatment and control groups were matched
ith regard to age, sex, blood pressure, and medication
Table 1). Patients and treating physicians were instructed
ot to change antihypertensive medication during the study,
nd RD and CPET were performed without any serious
dverse events in all patients.
Despite an intake of 5.7  1.4 antihypertensive drugs,
esting blood pressure at baseline was 172  24/94  19
m Hg in the intervention group and 166  23/90  7
m Hg in the control group, respectively (p  0.507 for
BP, p  0.579 for DBP). Blood pressure at maximum
xercise stage was 227  24/104  18 mm Hg without
ignificant differences between the groups (p  0.970 for
BP; p 0.915 for DBP) (Table 2). At 3-month follow-up,
esting blood pressure in the RD group was reduced by 31 
9/9 13 mm Hg (p 0.0001 for SBP and DBP), without
significant changes in the control group (Fig. 1). In patients
who underwent RD, maximum achieved work rate was
Abbreviations
and Acronyms
AT  anaerobic threshold
CI  chronotropic
incompetence
CPET  cardiopulmonary
exercise testing
DBP  diastolic blood
pressure
HRR  heart rate recovery
RD  renal sympathetic
denervation
SBP  systolic blood
pressure
VE/VCO2 slope 
ventilatory efficiency for
carbon dioxide
VO2AT  oxygen uptake at
anaerobic threshold
VO2peak  peak oxygen
uptakeincreased by 5 13 W (p 0.029), whereas blood pressure
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Exercise Parameters After Renal Denervation September 6, 2011:1176–82at maximum exercise was reduced by 21 20/5 14 mm Hg
(p 0.0001 for SBP; p 0.033 for DBP). RD reduced blood
pressure at all stages of exercise (Fig. 2), whereas there were no
hanges in the control group. Furthermore, SBP and DBP 2
in after termination of exercise were significantly reduced by
9 17/8 15 mm Hg (p 0.0001 for SBP; p 0.002 for
BP). A decrease of10 mm Hg of resting SBP was noticed
n 4 patients (11%) who underwent RD. However, 2 of these
onresponders had a reduction of maximum SBP during
xercise of 17 and 65 mm Hg, respectively. Twenty-four
atients (65%) in the RD group achieved blood pressure
Baseline CharacteristicsTable 1 Baseline Characteristics
All Patients
(N  46)
Age, yrs 60.2 9.1
Male 32 (70%)
Resting SBP, mm Hg 171 24
Resting DBP, mm Hg 93 18
Heart rate at rest, beats/min 73 13
eGFR, ml/min/1.73 m2 69 23
BMI, kg/m2 31.5 5.1
Type 2 diabetes 18 (39%)
Coronary artery disease 7 (15%)
Hypercholesterolemia 29 (63%)
Number of antihypertensive drugs 5.7 1.4
Patients receiving, drug class
ACE inhibitors/ARBs 42 (91%)
Direct renin inhibitors 13 (28%)
Beta-blockers 42 (91%)
Calcium-channel blockers 37 (80%)
Diuretics 40 (87%)
Sympatholytics 26 (57%)
Values are mean  SD or n (%). *For comparison between groups, th
ACE  angiotensin-converting enzyme; ARB  angiotensin recepto
estimated glomerular filtration rate; SBP  systolic blood pressure.
Resting and Exercise MeasurementsTable 2 Resting and Exercise Measurements
Renal Denervation Group
Baseline 3 Months Change
SBP at rest, mm Hg 172 24 141 21 31 19
DBP at rest, mm Hg 94 19 85 16 9 13
Heart rate at rest, beats/min 73 14 69 11 4 11
VO2AT, ml/min/kg 12 2 13 3 1 2
Maximum work rate, W 123 36 128 41 5 13
SBP at peak exercise, mm Hg 226 26 205 26 21 20
DBP at peak exercise, mm Hg 104 20 99 17 5 14
Heart rate at peak exercise, beats/min 118 19 115 19 3 11
VO2peak, ml/min/kg 19 4 19 5 0 2
Peak RER 1.03 0.10 1.06 0.10 0.03 0.
Peak minute ventilation, l/min 56 14 58 17 2 9
VE/VCO2 slope 26.7 5.7 27.4 4.8 0.7 7
SBP at recovery, mm Hg 203 24 174 20 29 17
DBP at recovery, mm Hg 99 16 91 15 8 15
Heart rate recovery, beats/min 16 9 20 10 4 7
Values are mean  SD. *p value  baseline versus 3-month follow-up. †p value  renal denerva
RER  respiratory exchange rate; VE/VCO2 minute ventilation – carbon dioxide output relation; VO2 
ther abbreviations as in Table 1.ontrol with a resting SBP of 140 mm Hg at 3-month
ollow-up. However, decrease of SBP at maximum exercise
as not different in these patients versus others in the RD
roup (22  19 mm Hg vs. 21  21 mm Hg; p  0.919).
Peak oxygen uptake (VO2peak) was different between the
groups at baseline and after 3 months. The peak respiratory
exchange rate (RER) at 3 months was 1.06 in both groups,
without any significant changes compared with the baseline
values (p  0.082 in RD; p  0.468 in control), indicating
comparable subjects’ effort stage. At baseline, VO2 at the
naerobic threshold (VO2AT) was 12  2 ml/min/kg in the
enal Denervation
(n  37)
Control Group
(n  9) p Value*
59.1 9.4 64.9 6.4 0.087
25 (68%) 7 (79%) 0.561
172 24 166 23 0.507
94 19 90 7 0.579
73 14 74 9 0.282
70 24 64.5 16 0.510
31.8 5.2 30.2 4.6 0.391
16 (43%) 2 (22%) 0.247
4 (11%) 3 (33%) 0.092
21 (57%) 8 (89%) 0.073
5.9 1.4 5.0 1.2 0.119
33 (89%) 9 (100%) 0.302
10 (27%) 3 (33%) 0.499
33 (89%) 9 (100%) 0.405
31 (84%) 6 (67%) 0.427
33 (89%) 7 (78%) 0.642
22 (60%) 4 (44%) 0.328
on chi-square test or Wilcoxon rank sum test was performed.
r; BMI  body mass index; DBP  diastolic blood pressure; eGFR 
Control Group
p Value†Value* Baseline 3 Months Change p Value*
0.0001 166 23 166 25 0 17 0.954 0.0001
0.0001 90 7 89 9 1 5 0.455 0.104
0.028 74 9 73 9 1 8 0.782 0.360
0.052 14 4 13 3 1 2 0.573 0.148
0.029 130 26 132 29 2 15 0.718 0.568
0.0001 227 16 229 10 2 10 0.542 0.001
0.033 104 11 100 9 4 10 0.324 0.725
0.141 125 25 125 27 0 12 0.936 0.570
0.486 20 4 21 5 1 2 0.376 0.641
0.082 1.08 0.10 1.06 0.10 0.02 0.10 0.468 0.159
0.209 57 12 55 12 2 8 0.535 0.281
0.514 27 3.3 25.6 4.3 1.4 2.0 0.116 0.349
0.0001 196 17 201 14 6 17 0.339 0.0001
0.002 92 10 92 8 1 9 0.476 0.144
0.009 22 9 20 8 2 6 0.928 0.048
up versus control group.R
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September 6, 2011:1176–82 Exercise Parameters After Renal DenervationRD group and 14  4 ml/min/kg in the control group. In
the RD group, VO2AT was significantly lower in diabetic
than in nondiabetic subjects (12  2 ml/min/kg vs. 13  2
ml/min/kg, p  0.045). After 3 months, a trend for an
increased VO2AT was noticed in treated subjects (1  2
l/min/kg; p  0.052). Other ventilatory parameters were
ot significantly different in both groups after 3 months
Table 2).
RD reduced heart rate at rest by 4  11 beats/min
compared with baseline values (p  0.028) (Fig. 3), in
particular in nondiabetic patients (–7  11 beats/min vs. 0 
10 beats/min in diabetic patients; p  0.037). The maxi-
um achieved heart rate was not significantly different
etween the groups (Fig. 4). Heart rate increase at different
xercise levels was not impaired after RD (Fig. 5). With a
ignificant number of patients being on beta-blockers
91%), the prevalence of chronotropic incompetence (CI)
efined as failure to achieve 80% of the maximum age-
redicted heart rate (7), was 78% (n  28) in the treatment
roup and 44% (n 4) in the control group, respectively. At
he 3-month visit, 1 additional patient in the control group
uffered from CI during exercise (28 patients [76%] in RD,
 1.0; 5 patients [56%] in control subjects, p  0.317).
ne minute after exercise termination, heart rate decreased
y 16  9 beats/min in the RD and by 22  9 beats/min in
he control group without significant differences between
roups (p  0.113). This HRR improved by 4  7
eats/min (p  0.009) 3 months after RD, whereas no
Figure 1 Changes of Blood Pressure
Changes of blood pressure at rest, at maximum work rate, and at recovery for ren
Error bars are 95% confidence intervals. DBP  diastolic blood pressure; SBP  shanges were noted in the control group. Beside changes of 1esting heart rate and VO2AT, no significant differences
etween diabetic and nondiabetic patients in the RD group
ere found.
iscussion
esides the known effect of RD on blood pressure at rest
3,4), our study showed for the first time that renal nerve
blation significantly reduces blood pressure during exercise
ith improvements in HRR without blood pressure dys-
egulation, ventilatory effects, or chronotropic incompe-
ence. Cardiopulmonary exercise tests are sufficient and
eproducible methods to investigate the neurovegetative
esponse to physical strain (8). Due to the reduction of
entral sympathetic activity by influencing renal afferent
erve activity, there might be the concern about impaired
ardiovascular response during exercise after RD (9).
Dynamic exercise is associated with a rise of cardiac
utput and a reduction in peripheral vascular resistance. As
consequence, SBP normally rises with increasing work rate
nd DBP remains the same or decreases slightly (10). Blood
ressure response to exercise can predict cardiovascular
orbidity and mortality independent of resting values
11,12). A 21-year follow-up study showed that a SBP of
200 mm Hg at 100 W was associated with higher
ardiovascular morality rates (13). Herein, patients with
esistant hypertension showed a rise of SBP of 55 mm Hg
uring exercise despite having a resting blood pressure of
ervation (RD) and control (C) groups.
blood pressure.al den
ystolic72/94 mm Hg. Three months after RD, SBP was reduced
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Exercise Parameters After Renal Denervation September 6, 2011:1176–82at all stages of exercise, without changes in concomitant
drug treatment. Moreover, the relative change of SBP
during exercise was maintained after RD, indicating a
physiological blood pressure adaption to increasing work
rates. SBP at 2 min after cessation of exercise decreased
Figure 2 SBP at Different Stages of Exercise
Systolic blood pressure in the RD (green) and C (yellow) groups at different stage
at baseline (solid) and 3 months (shaded). Error bars are standard error of the m
Figure 3 Changes of HR
Changes of heart rate (HR) at rest, peak HR, and HR recovery (peak HR –
HR 1 min after cessation of exercise) for RD and C groups. Error bars are
95% confidence intervals. bpm  beats/min; other abbreviations as in
Figure 1.from 203  24 mm Hg at baseline to 174  20 mm Hg
3 months after RD. There is evidence that SBP after
exercise provides prognostic information on cardiovascular
morbidity (14,15). Hence, RD led to a significant reduction
of blood pressure during exercise and recovery, without
hypotensive response or inadequate blood pressure rise
during exercise.
Exercise capacity can be determined by maximum
achieved work rate or by VO2peak. We observed a slight
mprovement of maximum work rate whereas VO2peak
remained unchanged after RD. In severe hypertension,
cardiac output can be limited by an excessive rise of SBP
(11). However, our patients showed no change of VO2peak,
surrogate parameter of maximal cardiac output during the
tudy period. RD elevated AT, indicating an improved
erobic capacity. The respiratory exchange ratio, as a key
arameter for inter- and intraindividual comparisons of
xercise exhaustion (7), was 1.0, indicating a sufficient
rade of patients’ exhaustion without being different be-
ween both groups or having changed after 3 months. This
rovides evidence that the observed changes are not related
o an increased or decreased level of effort or exhaustion in
he follow-up examination. Furthermore, we did not ob-
erve changes of minute ventilation or ventilatory efficiency.
hereas normal values of VE/VCO2 slope are considered
30, patients with heart failure can exceed this threshold by
ar (16,17). Although, chemosensitivity to carbon dioxide is
nfluenced by sympathetic drive (18), VE/VCO2 slope was
xercise (quartiles of maximum achieved work rate)
bbreviations as in Figure 1.s of e
ean. Anot changed after RD. However, ventilatory efficiency was
1181JACC Vol. 58, No. 11, 2011 Ukena et al.
September 6, 2011:1176–82 Exercise Parameters After Renal Denervationwithin normal limits in our study population. The effects of
RD in patients with impaired ventilatory efficiency, such as
heart failure, remain to be investigated.
Herein, patients after RD showed a reduced heart rate at
rest, in particular in nondiabetic patients. Heart rate is a
predictor of cardiovascular mortality and morbidity in the
Figure 4 HR at Different Stages of Exercise
Heart rate in the RD group at different stages of exercise (quartiles of maximum a
Error bars are standard error of the mean. Abbreviations as in Figures 1 and 3.
Figure 5 Change of HR at Different Stages of Exercise
Change in HR (difference between exercise HR and HR at rest) in the RD group
at different stages of exercise (quartiles of maximum achieved work rate) and
recovery at baseline and 3 months. Error bars are standard error of the mean.
Abbreviations as in Figures 1 and 3.general population, as well as in patients with hypertension
and heart failure (19–22). The less pronounced effect of RD
on heart rate reduction in diabetic patients may be explained
by cardiac autonomic neuropathy (23). CI represents an
inadequate rise of heart rate in response to exercise and can
be defined as failure to achieve 80% of the age-predicted
maximal heart rate. In subjects without heart rate–limiting
drugs, CI is associated with increased cardiovascular mor-
tality (24). There might be concerns that RD could possibly
lead to a reduced heart rate response during exercise.
However, heart rate adaption during exercise after RD was
not impaired. Due to the prevalence of beta-blockers treat-
ment, the observed prevalence of CI was high, but remained
unchanged after ablation of the renal sympathetic nerves. In
this study, we found significant improvement of HRR after
cessation of exercise in the intervention group. HRR was
identified as a predictor of mortality in healthy subjects and
in patients with cardiovascular disease (25–27). In patients
without previous known cardiovascular disease, the relative
risk of death was halved for a decrease by 9 beats/min in
HHR (25). Our findings indicate an improved HHR of 4
7 beats/min after RD. The beneficial effect on heart rate
could be explained by an improvement of autonomic bal-
ance after RD.
Study limitations. The control group consisted of 9 pa-
tients. Therefore, smaller differences between the treatment
group and the control group might not reach statistical
significance. The study was focused on the intragroup
changes after RD, whereas the control group was used to
d work rate) and recovery at baseline and 3 months.chievequantify the influence of repeated CPET. Twenty-eight
1182 Ukena et al. JACC Vol. 58, No. 11, 2011
Exercise Parameters After Renal Denervation September 6, 2011:1176–82patients of the present study were recruited for the extended
Symplicity HTN-2 trial in 2 investigation sites (Homburg/
Saar, Cologne). To avoid selection bias, the remaining 18
patients were included with the same inclusion and exclu-
sion criteria as in the Symplicity HTN-2 trial. All patients
were randomized to the control group or the RD group. As
is routinely performed in clinical practice, blood pressure
was measured noninvasively, which might lower the accu-
racy of the measurement during exercise; however, this
represents daily clinical practice. To minimize any interfer-
ence, blood pressure was measured by experienced physi-
cians who were blinded to randomization.
Conclusions
This study shows for the first time that RD reduces blood
pressure at rest, during physical exercise, and at recovery
without affecting the physiological cardiopulmonary re-
sponse to exercise. Whereas heart rate increase during
exercise was not impaired, heart rates at rest and at recovery
were significantly lower after RD. Our results support the
efficacy and safety of RD in the treatment of resistant
hypertension.
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Dr. Felix Mahfoud, Klinik für Innere Medizin III, Kardiologie,
Angiologie und Internistische Intensivmedizin, Kirrberger 1,
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